Maple Grove, MN - June 23, 2020 - Upsher-Smith Laboratories, LLC (Upsher-Smith, President and CEO: Rusty Field), a subsidiary of Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) today announced the launch of Ethacrynic Acid Tablets, USP in 25 mg strength (the branded product: Edecrin®). The product was approved by the U.S. Food and Drug Administration (FDA).
Ethacrynic Acid Tablets 25 mg is prescribed for treatment of edema when an agent with greater diuretic potential than those commonly employed is required.
- Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.
- Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema.
- Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome.
The ethacrynic acid tablet market had U.S. sales of approximately $17 million for the 12 months ending April 2020 according to IQVIA.
*Edecrin is a trademark of Bausch Health Ireland Limited.
About Upsher-Smith
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. Since 1919, it has brought generics and brands to a wide array of customers backed by an attentive level of service, strong industry relationships, and dedication to uninterrupted supply.
As Upsher-Smith begins its second century in business, the company enters a new ambitious era that has been accelerated by its 2017 acquisition by Sawai Pharmaceutical Co., Ltd. Upsher-Smith and Sawai plan to leverage each other for growth worldwide and embark on an exciting new chapter as they seek to deliver the best value for their stakeholders, and most importantly, Do More Good™ for the patients they serve. For more information, visit www.upsher-smith.com/.